Clinical Trial: Tysabri® (natalizumab) - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: Tysabri® (natalizumab)

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 300
Medication: Tysabri
Location: Alabama|Arizona|California|Colorado|Delaware|District of Columbia|Florida|Georgia|Illinois|Indiana|Kansas|Kentucky|Massachusetts|Michigan|New York|North Carolina|Ohio|Oregon|Pennsylvania|Texas|Utah|Virginia|Washington
Contact Information
neurologyclinicaltrials@biogenidec.com

Funding:

Biogen Idec

Description

A multicenter, observational, open label study of to determine effectiveness in early relapsing remitting multiple sclerosis.

Share